<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">37425897</PMID><DateRevised><Year>2023</Year><Month>11</Month><Day>06</Day></DateRevised><Article PubModel="Electronic"><Journal><JournalIssue CitedMedium="Internet"><PubDate><Year>2023</Year><Month>Jun</Month><Day>29</Day></PubDate></JournalIssue><Title>medRxiv : the preprint server for health sciences</Title><ISOAbbreviation>medRxiv</ISOAbbreviation></Journal><ArticleTitle>Increased circulating fibronectin, depletion of natural IgM and heightened EBV, HSV-1 reactivation in ME/CFS and long COVID.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">2023.06.23.23291827</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1101/2023.06.23.23291827</ELocationID><Abstract><AbstractText>Myalgic Encephalomyelitis/ Chronic Fatigue syndrome (ME/CFS) is a complex, debilitating, long-term illness without a diagnostic biomarker. ME/CFS patients share overlapping symptoms with long COVID patients, an observation which has strengthened the infectious origin hypothesis of ME/CFS. However, the exact sequence of events leading to disease development is largely unknown for both clinical conditions. Here we show antibody response to herpesvirus dUTPases, particularly to that of Epstein-Barr virus (EBV) and HSV-1, increased circulating fibronectin (FN1) levels in serum and depletion of natural IgM against fibronectin ((n)IgM-FN1) are common factors for both severe ME/CFS and long COVID. We provide evidence for herpesvirus dUTPases-mediated alterations in host cell cytoskeleton, mitochondrial dysfunction and OXPHOS. Our data show altered active immune complexes, immunoglobulin-mediated mitochondrial fragmentation as well as adaptive IgM production in ME/CFS patients. Our findings provide mechanistic insight into both ME/CFS and long COVID development. Finding of increased circulating FN1 and depletion of (n)IgM-FN1 as a biomarker for the severity of both ME/CFS and long COVID has an immediate implication in diagnostics and development of treatment modalities.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Zheng</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Institute for Virology and Immunobiology, Julius-Maximilians-University of W&#xfc;rzburg, W&#xfc;rzburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hollmann</LastName><ForeName>Claudia</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Institute for Virology and Immunobiology, Julius-Maximilians-University of W&#xfc;rzburg, W&#xfc;rzburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kalanidhi</LastName><ForeName>Sharada</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Stanford Genome Technology Center, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grothey</LastName><ForeName>Arnhild</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Institute for Virology and Immunobiology, Julius-Maximilians-University of W&#xfc;rzburg, W&#xfc;rzburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Keating</LastName><ForeName>Sam</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Institute for Virology and Immunobiology, Julius-Maximilians-University of W&#xfc;rzburg, W&#xfc;rzburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mena-Palomo</LastName><ForeName>Irene</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Institute for Medical Data Sciences, University Hospital W&#xfc;rzburg, W&#xfc;rzburg.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lamer</LastName><ForeName>Stephanie</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Rudolf Virchow Center, Center for Translational Bioimaging, Julius-Maximilians-University of W&#xfc;rzburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schlosser</LastName><ForeName>Andreas</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Rudolf Virchow Center, Center for Translational Bioimaging, Julius-Maximilians-University of W&#xfc;rzburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kaiping</LastName><ForeName>Agnes</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Institute for Virology and Immunobiology, Julius-Maximilians-University of W&#xfc;rzburg, W&#xfc;rzburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scheller</LastName><ForeName>Carsten</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Institute for Virology and Immunobiology, Julius-Maximilians-University of W&#xfc;rzburg, W&#xfc;rzburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sotzny</LastName><ForeName>Franzeska</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Institute for Medical Immunology, Charit&#xe9;-Universit&#xe4;tsmedizin Berlin, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Horn</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Institute of Clinical Epidemiology and Biometry, Julius-Maximilians-University of W&#xfc;rzburg, W&#xfc;rzburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>N&#xfc;rnberger</LastName><ForeName>Carolin</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Institute of Clinical Epidemiology and Biometry, Julius-Maximilians-University of W&#xfc;rzburg, W&#xfc;rzburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cejka</LastName><ForeName>Vladimir</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Clinical Research &amp; Epidemiology, Comprehensive Heart Failure Center and Department of Medicine I, University Hospital W&#xfc;rzburg, W&#xfc;rzburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Afshar</LastName><ForeName>Boshra</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Institute for Virology and Immunobiology, Julius-Maximilians-University of W&#xfc;rzburg, W&#xfc;rzburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bahmer</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Internal Medicine Department I, University Hospital Schleswig-Holstein UKSH - Campus Kiel, Kiel, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schreiber</LastName><ForeName>Stefan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Internal Medicine Department I, University Hospital Schleswig-Holstein UKSH - Campus Kiel, Kiel, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vehreschild</LastName><ForeName>J&#xf6;rg Janne</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>University of Cologne, Faculty of Medicine and University Hospital Cologne, Department of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miljukov</LastName><ForeName>Olga</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Institute of Clinical Epidemiology and Biometry, Julius-Maximilians-University of W&#xfc;rzburg, W&#xfc;rzburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sch&#xe4;fer</LastName><ForeName>Christian</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>University Medicine Greifswald, Institute of Clinical Chemistry and Laboratory Medicine, Greifswald, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kretzler</LastName><ForeName>Luzie</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Charit&#xe9; - Universit&#xe4;tsmedizin Berlin and Berlin Institute of Health (BIH), Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Keil</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Charit&#xe9; - Universit&#xe4;tsmedizin Berlin and Berlin Institute of Health (BIH), Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reese</LastName><ForeName>Jens-Peter</ForeName><Initials>JP</Initials><AffiliationInfo><Affiliation>Institute of Clinical Epidemiology and Biometry, Julius-Maximilians-University of W&#xfc;rzburg, W&#xfc;rzburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eichner</LastName><ForeName>Felizitas A</ForeName><Initials>FA</Initials><AffiliationInfo><Affiliation>Institute of Clinical Epidemiology and Biometry, Julius-Maximilians-University of W&#xfc;rzburg, W&#xfc;rzburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schmidbauer</LastName><ForeName>Lena</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Institute of Clinical Epidemiology and Biometry, Julius-Maximilians-University of W&#xfc;rzburg, W&#xfc;rzburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Heuschmann</LastName><ForeName>Peter U</ForeName><Initials>PU</Initials><AffiliationInfo><Affiliation>Institute of Clinical Epidemiology and Biometry, Julius-Maximilians-University of W&#xfc;rzburg, W&#xfc;rzburg, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute for Medical Data Sciences, University Hospital W&#xfc;rzburg, W&#xfc;rzburg.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Trial Center, University Hospital W&#xfc;rzburg, W&#xfc;rzburg.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>St&#xf6;rk</LastName><ForeName>Stefan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Clinical Research &amp; Epidemiology, Comprehensive Heart Failure Center and Department of Medicine I, University Hospital W&#xfc;rzburg, W&#xfc;rzburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morbach</LastName><ForeName>Caroline</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Clinical Research &amp; Epidemiology, Comprehensive Heart Failure Center and Department of Medicine I, University Hospital W&#xfc;rzburg, W&#xfc;rzburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Riemekasten</LastName><ForeName>Gabriela</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Klinik f&#xfc;r Rheumatologie, Universit&#xe4;tsklinikum Schleswig-Holstein, L&#xfc;beck.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beyersdorf</LastName><ForeName>Niklas</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Institute for Virology and Immunobiology, Julius-Maximilians-University of W&#xfc;rzburg, W&#xfc;rzburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scheibenbogen</LastName><ForeName>Carmen</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Institute for Medical Immunology, Charit&#xe9;-Universit&#xe4;tsmedizin Berlin, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Naviaux</LastName><ForeName>Robert K</ForeName><Initials>RK</Initials><AffiliationInfo><Affiliation>Departments of Medicine, Pediatrics, and Pathology, University of California, San Diego School of Medicine, San Diego, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Williams</LastName><ForeName>Marshall</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute for Behavioral Medicine Research (IBMR), The Ohio State University, Columbus, Ohio, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ariza</LastName><ForeName>Maria E</ForeName><Initials>ME</Initials><AffiliationInfo><Affiliation>Institute for Behavioral Medicine Research (IBMR), The Ohio State University, Columbus, Ohio, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prusty</LastName><ForeName>Bhupesh K</ForeName><Initials>BK</Initials><AffiliationInfo><Affiliation>Institute for Virology and Immunobiology, Julius-Maximilians-University of W&#xfc;rzburg, W&#xfc;rzburg, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AI084898</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D000076942">Preprint</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>06</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>medRxiv</MedlineTA><NlmUniqueID>101767986</NlmUniqueID></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">(n)IgM</Keyword><Keyword MajorTopicYN="N">EBV</Keyword><Keyword MajorTopicYN="N">Fibronectin</Keyword><Keyword MajorTopicYN="N">HHV-6</Keyword><Keyword MajorTopicYN="N">HSV-1</Keyword><Keyword MajorTopicYN="N">ME/CFS</Keyword><Keyword MajorTopicYN="N">dUTPase</Keyword><Keyword MajorTopicYN="N">long COVID</Keyword></KeywordList><CoiStatement>Competing Interests: The authors declare that they have no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>7</Month><Day>10</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>7</Month><Day>10</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>7</Month><Day>10</Day><Hour>5</Hour><Minute>2</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>7</Month><Day>7</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37425897</ArticleId><ArticleId IdType="pmc">PMC10327231</ArticleId><ArticleId IdType="doi">10.1101/2023.06.23.23291827</ArticleId><ArticleId IdType="pii">2023.06.23.23291827</ArticleId></ArticleIdList><ReferenceList><Title>References for Methods:</Title><Reference><Citation>Bahmer T. et al. Severity, predictors and clinical correlates of Post-COVID syndrome (PCS) in Germany: A prospective, multi-centre, population-based cohort study. EClinicalMedicine 51, 101549, doi:10.1016/j.eclinm.2022.101549 (2022).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2022.101549</ArticleId><ArticleId IdType="pmc">PMC9289961</ArticleId><ArticleId IdType="pubmed">35875815</ArticleId></ArticleIdList></Reference><Reference><Citation>Horn A. et al. Long-term health sequelae and quality of life at least 6 months after infection with SARS-CoV-2: design and rationale of the COVIDOM-study as part of the NAPKON population-based cohort platform (POP). Infection 49, 1277&#x2013;1287, doi:10.1007/s15010-021-01707-5 (2021).</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s15010-021-01707-5</ArticleId><ArticleId IdType="pmc">PMC8508400</ArticleId><ArticleId IdType="pubmed">34642875</ArticleId></ArticleIdList></Reference><Reference><Citation>Wagner M. et al. Characteristics and Course of Heart Failure Stages A-B and Determinants of Progression - design and rationale of the STAAB cohort study. Eur J Prev Cardiol 24, 468&#x2013;479, doi:10.1177/2047487316680693 (2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/2047487316680693</ArticleId><ArticleId IdType="pubmed">27879413</ArticleId></ArticleIdList></Reference><Reference><Citation>Morbach C. et al. Prevalence and determinants of the precursor stages of heart failure: results from the population-based STAAB cohort study. Eur J Prev Cardiol 28, 924&#x2013;934, doi:10.1177/2047487320922636 (2021).</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/2047487320922636</ArticleId><ArticleId IdType="pubmed">34402874</ArticleId></ArticleIdList></Reference><Reference><Citation>Hennig T. et al. Selective inhibition of miRNA processing by a herpesvirus-encoded miRNA. Nature 605, 539&#x2013;544, doi:10.1038/s41586-022-04667-4 (2022).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-04667-4</ArticleId><ArticleId IdType="pubmed">35508655</ArticleId></ArticleIdList></Reference><Reference><Citation>Chowdhury S. R. et al. Chlamydia preserves the mitochondrial network necessary for replication via microRNA-dependent inhibition of fission. J Cell Biol 216, 1071&#x2013;1089, doi:10.1083/jcb.201608063 (2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.1083/jcb.201608063</ArticleId><ArticleId IdType="pmc">PMC5379946</ArticleId><ArticleId IdType="pubmed">28330939</ArticleId></ArticleIdList></Reference><Reference><Citation>Schindelin J. et al. Fiji: an open-source platform for biological-image analysis. Nat Methods 9, 676&#x2013;682, doi:10.1038/nmeth.2019 (2012).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nmeth.2019</ArticleId><ArticleId IdType="pmc">PMC3855844</ArticleId><ArticleId IdType="pubmed">22743772</ArticleId></ArticleIdList></Reference><Reference><Citation>Prusty B. K., Chowdhury S. R., Gulve N. &amp; Rudel T. Peptidase Inhibitor 15 (PI15) Regulates Chlamydial CPAF Activity. Front Cell Infect Microbiol 8, 183, doi:10.3389/fcimb.2018.00183 (2018).</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcimb.2018.00183</ArticleId><ArticleId IdType="pmc">PMC5989220</ArticleId><ArticleId IdType="pubmed">29900129</ArticleId></ArticleIdList></Reference><Reference><Citation>Gulve N. et al. Anti-herpesviral effects of a novel broad range anti-microbial quaternary ammonium silane, K21. Antiviral Res 131, 166&#x2013;173, doi:10.1016/j.antiviral.2016.05.004 (2016).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2016.05.004</ArticleId><ArticleId IdType="pubmed">27181377</ArticleId></ArticleIdList></Reference><Reference><Citation>Hughes C. S. et al. Single-pot, solid-phase-enhanced sample preparation for proteomics experiments. Nat Protoc 14, 68&#x2013;85, doi:10.1038/s41596-018-0082-x (2019).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41596-018-0082-x</ArticleId><ArticleId IdType="pubmed">30464214</ArticleId></ArticleIdList></Reference><Reference><Citation>Rappsilber J., Ishihama Y. &amp; Mann M. Stop and go extraction tips for matrix-assisted laser desorption/ionization, nanoelectrospray, and LC/MS sample pretreatment in proteomics. Anal Chem 75, 663&#x2013;670, doi:10.1021/ac026117i (2003).</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/ac026117i</ArticleId><ArticleId IdType="pubmed">12585499</ArticleId></ArticleIdList></Reference><Reference><Citation>Cox J. &amp; Mann M. MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. Nat Biotechnol 26, 1367&#x2013;1372, doi:10.1038/nbt.1511 (2008).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nbt.1511</ArticleId><ArticleId IdType="pubmed">19029910</ArticleId></ArticleIdList></Reference><Reference><Citation>Cox J. et al. Accurate proteome-wide label-free quantification by delayed normalization and maximal peptide ratio extraction, termed MaxLFQ. Mol Cell Proteomics 13, 2513&#x2013;2526, doi:10.1074/mcp.M113.031591 (2014).</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/mcp.M113.031591</ArticleId><ArticleId IdType="pmc">PMC4159666</ArticleId><ArticleId IdType="pubmed">24942700</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Davis H. E., McCorkell L., Vogel J. M. &amp; Topol E. J. Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol 21, 133&#x2013;146, doi:10.1038/s41579-022-00846-2 (2023).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-022-00846-2</ArticleId><ArticleId IdType="pmc">PMC9839201</ArticleId><ArticleId IdType="pubmed">36639608</ArticleId></ArticleIdList></Reference><Reference><Citation>Banko A., Miljanovic D. &amp; Cirkovic A. Systematic review with meta-analysis of active herpesvirus infections in patients with COVID-19: Old players on the new field. Int J Infect Dis 130, 108&#x2013;125, doi:10.1016/j.ijid.2023.01.036 (2023).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2023.01.036</ArticleId><ArticleId IdType="pmc">PMC9889115</ArticleId><ArticleId IdType="pubmed">36736577</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein J. et al. Distinguishing features of Long COVID identified through immune profiling. medRxiv, doi:10.1101/2022.08.09.22278592 (2022).</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2022.08.09.22278592</ArticleId><ArticleId IdType="pmc">PMC10620090</ArticleId><ArticleId IdType="pubmed">37748514</ArticleId></ArticleIdList></Reference><Reference><Citation>Rasa S. et al. Chronic viral infections in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). J Transl Med 16, 268, doi:10.1186/s12967-018-1644-y (2018).</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12967-018-1644-y</ArticleId><ArticleId IdType="pmc">PMC6167797</ArticleId><ArticleId IdType="pubmed">30285773</ArticleId></ArticleIdList></Reference><Reference><Citation>Kasimir F. et al. Tissue specific signature of HHV-6 infection in ME/CFS. Front Mol Biosci 9, 1044964, doi:10.3389/fmolb.2022.1044964 (2022).</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmolb.2022.1044964</ArticleId><ArticleId IdType="pmc">PMC9795011</ArticleId><ArticleId IdType="pubmed">36589231</ArticleId></ArticleIdList></Reference><Reference><Citation>Bahmer T. et al. Severity, predictors and clinical correlates of Post-COVID syndrome (PCS) in Germany: A prospective, multi-centre, population-based cohort study. EClinicalMedicine 51, 101549, doi:10.1016/j.eclinm.2022.101549 (2022).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2022.101549</ArticleId><ArticleId IdType="pmc">PMC9289961</ArticleId><ArticleId IdType="pubmed">35875815</ArticleId></ArticleIdList></Reference><Reference><Citation>Hartung T. J. et al. Fatigue and cognitive impairment after COVID-19: A prospective multicentre study. EClinicalMedicine 53, 101651, doi:10.1016/j.eclinm.2022.101651 (2022).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2022.101651</ArticleId><ArticleId IdType="pmc">PMC9482331</ArticleId><ArticleId IdType="pubmed">36133318</ArticleId></ArticleIdList></Reference><Reference><Citation>Tondera D. et al. SLP-2 is required for stress-induced mitochondrial hyperfusion. The EMBO Journal 28, 1589&#x2013;1600, doi:10.1038/emboj.2009.89 (2009).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/emboj.2009.89</ArticleId><ArticleId IdType="pmc">PMC2693158</ArticleId><ArticleId IdType="pubmed">19360003</ArticleId></ArticleIdList></Reference><Reference><Citation>Das R. &amp; Chakrabarti O. Mitochondrial hyperfusion: a friend or a foe. Biochem Soc Trans 48, 631&#x2013;644, doi:10.1042/BST20190987 (2020).</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/BST20190987</ArticleId><ArticleId IdType="pubmed">32219382</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai M. et al. Characterization of the subcellular localization of Epstein-Barr virus encoded proteins in live cells. Oncotarget 8, 70006&#x2013;70034, doi:10.18632/oncotarget.19549 (2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/oncotarget.19549</ArticleId><ArticleId IdType="pmc">PMC5642534</ArticleId><ArticleId IdType="pubmed">29050259</ArticleId></ArticleIdList></Reference><Reference><Citation>Menges S. et al. Alpha-synuclein prevents the formation of spherical mitochondria and apoptosis under oxidative stress. Sci Rep 7, 42942, doi:10.1038/srep42942 (2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep42942</ArticleId><ArticleId IdType="pmc">PMC5320486</ArticleId><ArticleId IdType="pubmed">28224980</ArticleId></ArticleIdList></Reference><Reference><Citation>Houen G. &amp; Trier N. H. Epstein-Barr Virus and Systemic Autoimmune Diseases. Front Immunol 11, 587380, doi:10.3389/fimmu.2020.587380 (2020).</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.587380</ArticleId><ArticleId IdType="pmc">PMC7817975</ArticleId><ArticleId IdType="pubmed">33488588</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao Z. S., Granucci F., Yeh L., Schaffer P. A. &amp; Cantor H. Molecular mimicry by herpes simplex virus-type 1: autoimmune disease after viral infection. Science 279, 1344&#x2013;1347, doi:10.1126/science.279.5355.1344 (1998).</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.279.5355.1344</ArticleId><ArticleId IdType="pubmed">9478893</ArticleId></ArticleIdList></Reference><Reference><Citation>Kadaja L. et al. IgG from patients with liver diseases inhibit mitochondrial respiration in permeabilized oxidative muscle cells: impaired function of intracellular energetic units? Mol Cell Biochem 256&#x2013;257, 291&#x2013;303, doi:10.1023/b:mcbi.0000009876.23921.e6 (2004).</Citation><ArticleIdList><ArticleId IdType="doi">10.1023/b:mcbi.0000009876.23921.e6</ArticleId><ArticleId IdType="pubmed">14977189</ArticleId></ArticleIdList></Reference><Reference><Citation>Cho S. et al. Neuromyelitis optica (NMO)-IgG-driven organelle reorganization in human iPSC-derived astrocytes. FASEB J 35, e21894, doi:10.1096/fj.202100637R (2021).</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.202100637R</ArticleId><ArticleId IdType="pubmed">34460995</ArticleId></ArticleIdList></Reference><Reference><Citation>Rostagno A. A., Frangione B. &amp; Gold L. Biochemical studies on the interaction of fibronectin with Ig. J Immunol 146, 2687&#x2013;2693 (1991).</Citation><ArticleIdList><ArticleId IdType="pubmed">2016522</ArticleId></ArticleIdList></Reference><Reference><Citation>Bray B. A., Osman M. &amp; Turino G. M. Evidence that fibronectin-immunoglobulin complexes occur normally in plasma. Proc Soc Exp Biol Med 207, 324&#x2013;331, doi:10.3181/00379727-207-43823 (1994).</Citation><ArticleIdList><ArticleId IdType="doi">10.3181/00379727-207-43823</ArticleId><ArticleId IdType="pubmed">7800689</ArticleId></ArticleIdList></Reference><Reference><Citation>Truyens C., Rivera M. T., Ouaissi A. &amp; Carlier Y. High circulating levels of fibronectin and antibodies against its RGD adhesion site during mouse Trypanosoma cruzi infection: relation to survival. Exp Parasitol 80, 499&#x2013;506, doi:10.1006/expr.1995.1062 (1995).</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/expr.1995.1062</ArticleId><ArticleId IdType="pubmed">7729485</ArticleId></ArticleIdList></Reference><Reference><Citation>Baumgarth N. The double life of a B-1 cell: self-reactivity selects for protective effector functions. Nat Rev Immunol 11, 34&#x2013;46, doi:10.1038/nri2901 (2011).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri2901</ArticleId><ArticleId IdType="pubmed">21151033</ArticleId></ArticleIdList></Reference><Reference><Citation>Ehrenstein M. R. &amp; Notley C. A. The importance of natural IgM: scavenger, protector and regulator. Nat Rev Immunol 10, 778&#x2013;786, doi:10.1038/nri2849 (2010).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri2849</ArticleId><ArticleId IdType="pubmed">20948548</ArticleId></ArticleIdList></Reference><Reference><Citation>Halpin P. et al. Myalgic encephalomyelitis/chronic fatigue syndrome and gulf war illness patients exhibit increased humoral responses to the herpesviruses-encoded dUTPase: Implications in disease pathophysiology. J Med Virol 89, 1636&#x2013;1645, doi:10.1002/jmv.24810 (2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.24810</ArticleId><ArticleId IdType="pmc">PMC5513753</ArticleId><ArticleId IdType="pubmed">28303641</ArticleId></ArticleIdList></Reference><Reference><Citation>Chu V. T. et al. Systemic activation of the immune system induces aberrant BAFF and APRIL expression in B cells in patients with systemic lupus erythematosus. Arthritis Rheum 60, 2083&#x2013;2093, doi:10.1002/art.24628 (2009).</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.24628</ArticleId><ArticleId IdType="pubmed">19565488</ArticleId></ArticleIdList></Reference><Reference><Citation>Al Tabaa Y. et al. Functional Epstein-Barr virus reservoir in plasma cells derived from infected peripheral blood memory B cells. Blood 113, 604&#x2013;611, doi:10.1182/blood-2008-02-136903 (2009).</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2008-02-136903</ArticleId><ArticleId IdType="pubmed">18845794</ArticleId></ArticleIdList></Reference><Reference><Citation>Laichalk L. L. &amp; Thorley-Lawson D. A. Terminal differentiation into plasma cells initiates the replicative cycle of Epstein-Barr virus in vivo. J Virol 79, 1296&#x2013;1307, doi:10.1128/JVI.79.2.1296-1307.2005 (2005).</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.79.2.1296-1307.2005</ArticleId><ArticleId IdType="pmc">PMC538585</ArticleId><ArticleId IdType="pubmed">15613356</ArticleId></ArticleIdList></Reference><Reference><Citation>Wen Z. et al. Autoantibody induction by DNA-containing immune complexes requires HMGB1 with the TLR2/microRNA-155 pathway. J Immunol 190, 5411&#x2013;5422, doi:10.4049/jimmunol.1203301 (2013).</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1203301</ArticleId><ArticleId IdType="pubmed">23616573</ArticleId></ArticleIdList></Reference><Reference><Citation>Cox B. S., Alharshawi K., Mena-Palomo I., Lafuse W. P. &amp; Ariza M. E. EBV/HHV-6A dUTPases contribute to myalgic encephalomyelitis/chronic fatigue syndrome pathophysiology by enhancing TFH cell differentiation and extrafollicular activities. JCI Insight 7, doi:10.1172/jci.insight.158193 (2022).</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.158193</ArticleId><ArticleId IdType="pmc">PMC9220958</ArticleId><ArticleId IdType="pubmed">35482424</ArticleId></ArticleIdList></Reference><Reference><Citation>Ariza M. E., Rivailler P., Glaser R., Chen M. &amp; Williams M. V. Epstein-Barr virus encoded dUTPase containing exosomes modulate innate and adaptive immune responses in human dendritic cells and peripheral blood mononuclear cells. PLoS One 8, e69827, doi:10.1371/journal.pone.0069827 (2013).</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0069827</ArticleId><ArticleId IdType="pmc">PMC3718799</ArticleId><ArticleId IdType="pubmed">23894549</ArticleId></ArticleIdList></Reference><Reference><Citation>Lerner A. M. et al. Antibody to Epstein-Barr virus deoxyuridine triphosphate nucleotidohydrolase and deoxyribonucleotide polymerase in a chronic fatigue syndrome subset. PLoS One 7, e47891, doi:10.1371/journal.pone.0047891 (2012).</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0047891</ArticleId><ArticleId IdType="pmc">PMC3498272</ArticleId><ArticleId IdType="pubmed">23155374</ArticleId></ArticleIdList></Reference><Reference><Citation>Sandvik M. K. et al. Endothelial dysfunction in ME/CFS patients. PLoS One 18, e0280942, doi:10.1371/journal.pone.0280942 (2023).</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0280942</ArticleId><ArticleId IdType="pmc">PMC9894436</ArticleId><ArticleId IdType="pubmed">36730360</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahamed J. &amp; Laurence J. Long COVID endotheliopathy: hypothesized mechanisms and potential therapeutic approaches. J Clin Invest 132, doi:10.1172/JCI161167 (2022).</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI161167</ArticleId><ArticleId IdType="pmc">PMC9337829</ArticleId><ArticleId IdType="pubmed">35912863</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Yafeai Z. et al. Endothelial FN (Fibronectin) Deposition by alpha5beta1 Integrins Drives Atherogenic Inflammation. Arterioscler Thromb Vasc Biol 38, 2601&#x2013;2614, doi:10.1161/ATVBAHA.118.311705 (2018).</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/ATVBAHA.118.311705</ArticleId><ArticleId IdType="pmc">PMC6209122</ArticleId><ArticleId IdType="pubmed">30354234</ArticleId></ArticleIdList></Reference><Reference><Citation>Cosio F. G., Mahan J. D. &amp; Sedmak D. D. Experimental glomerulonephritis induced by antigen that binds to glomerular fibronectin. Am J Kidney Dis 15, 160&#x2013;168, doi:10.1016/s0272-6386(12)80514-2 (1990).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0272-6386(12)80514-2</ArticleId><ArticleId IdType="pubmed">2301387</ArticleId></ArticleIdList></Reference><Reference><Citation>Niddam A. F. et al. Plasma fibronectin stabilizes Borrelia burgdorferi-endothelial interactions under vascular shear stress by a catch-bond mechanism. Proceedings of the National Academy of Sciences of the United States of America 114, E3490&#x2013;E3498, doi:10.1073/pnas.1615007114 (2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1615007114</ArticleId><ArticleId IdType="pmc">PMC5410840</ArticleId><ArticleId IdType="pubmed">28396443</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen H. Y., Lin M. H., Chen C. C. &amp; Shu J. C. The expression of fibronectin is significantly suppressed in macrophages to exert a protective effect against Staphylococcus aureus infection. BMC Microbiol 17, 92, doi:10.1186/s12866-017-1003-9 (2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12866-017-1003-9</ArticleId><ArticleId IdType="pmc">PMC5390343</ArticleId><ArticleId IdType="pubmed">28407745</ArticleId></ArticleIdList></Reference><Reference><Citation>Brissette C. A. et al. The borrelial fibronectin-binding protein RevA is an early antigen of human Lyme disease. Clin Vaccine Immunol 17, 274&#x2013;280, doi:10.1128/CVI.00437-09 (2010).</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/CVI.00437-09</ArticleId><ArticleId IdType="pmc">PMC2815533</ArticleId><ArticleId IdType="pubmed">20032216</ArticleId></ArticleIdList></Reference><Reference><Citation>Herbert K. E. et al. Fibronectin and immune complexes in rheumatic diseases. Ann Rheum Dis 46, 734&#x2013;740, doi:10.1136/ard.46.10.734 (1987).</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ard.46.10.734</ArticleId><ArticleId IdType="pmc">PMC1003379</ArticleId><ArticleId IdType="pubmed">3500676</ArticleId></ArticleIdList></Reference><Reference><Citation>Bing D. H., Almeda S., Isliker H., Lahav J. &amp; Hynes R. O. Fibronectin binds to the C1q component of complement. Proceedings of the National Academy of Sciences of the United States of America 79, 4198&#x2013;4201, doi:10.1073/pnas.79.13.4198 (1982).</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.79.13.4198</ArticleId><ArticleId IdType="pmc">PMC346605</ArticleId><ArticleId IdType="pubmed">6981115</ArticleId></ArticleIdList></Reference><Reference><Citation>Sandig H. et al. Fibronectin is a TH1-specific molecule in human subjects. The Journal of allergy and clinical immunology 124, 528&#x2013;535, 535 e521&#x2013;525, doi:10.1016/j.jaci.2009.04.036 (2009).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaci.2009.04.036</ArticleId><ArticleId IdType="pubmed">19541353</ArticleId></ArticleIdList></Reference><Reference><Citation>Kelsh R., You R., Horzempa C., Zheng M. &amp; McKeown-Longo P. J. Regulation of the innate immune response by fibronectin: synergism between the III-1 and EDA domains. PLoS One 9, e102974, doi:10.1371/journal.pone.0102974 (2014).</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0102974</ArticleId><ArticleId IdType="pmc">PMC4106844</ArticleId><ArticleId IdType="pubmed">25051083</ArticleId></ArticleIdList></Reference><Reference><Citation>Thurlow P. J., Kenneally D. A. &amp; Connellan J. M. The role of fibronectin in platelet aggregation. Br J Haematol 75, 549&#x2013;556, doi:10.1111/j.1365-2141.1990.tb07797.x (1990).</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2141.1990.tb07797.x</ArticleId><ArticleId IdType="pubmed">2207006</ArticleId></ArticleIdList></Reference><Reference><Citation>Gondokaryono S. P. et al. The extra domain A of fibronectin stimulates murine mast cells via toll-like receptor 4. J Leukoc Biol 82, 657&#x2013;665, doi:10.1189/jlb.1206730 (2007).</Citation><ArticleIdList><ArticleId IdType="doi">10.1189/jlb.1206730</ArticleId><ArticleId IdType="pubmed">17575266</ArticleId></ArticleIdList></Reference><Reference><Citation>Dziarski R. Modulation of polyclonal activation by plasma fibronectin and fibronectin fragments. Immunology 61, 111&#x2013;116 (1987).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1453372</ArticleId><ArticleId IdType="pubmed">3298022</ArticleId></ArticleIdList></Reference><Reference><Citation>Gronwall C., Vas J. &amp; Silverman G. J. Protective Roles of Natural IgM Antibodies. Front Immunol 3, 66, doi:10.3389/fimmu.2012.00066 (2012).</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2012.00066</ArticleId><ArticleId IdType="pmc">PMC3341951</ArticleId><ArticleId IdType="pubmed">22566947</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein S. L. &amp; Flanagan K. L. Sex differences in immune responses. Nat Rev Immunol 16, 626&#x2013;638, doi:10.1038/nri.2016.90 (2016).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri.2016.90</ArticleId><ArticleId IdType="pubmed">27546235</ArticleId></ArticleIdList></Reference><Reference><Citation>Panda S., Zhang J., Tan N. S., Ho B. &amp; Ding J. L. Natural IgG antibodies provide innate protection against ficolin-opsonized bacteria. The EMBO Journal 32, 2905&#x2013;2919, doi:10.1038/emboj.2013.199 (2013).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/emboj.2013.199</ArticleId><ArticleId IdType="pmc">PMC3831310</ArticleId><ArticleId IdType="pubmed">24002211</ArticleId></ArticleIdList></Reference><Reference><Citation>Quach T. D. et al. Distinctions among Circulating Antibody-Secreting Cell Populations, Including B-1 Cells, in Human Adult Peripheral Blood. J Immunol 196, 1060&#x2013;1069, doi:10.4049/jimmunol.1501843 (2016).</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1501843</ArticleId><ArticleId IdType="pmc">PMC5351554</ArticleId><ArticleId IdType="pubmed">26740107</ArticleId></ArticleIdList></Reference><Reference><Citation>Mina M. J. et al. Measles virus infection diminishes preexisting antibodies that offer protection from other pathogens. Science 366, 599&#x2013;606, doi:10.1126/science.aay6485 (2019).</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aay6485</ArticleId><ArticleId IdType="pmc">PMC8590458</ArticleId><ArticleId IdType="pubmed">31672891</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith F. L. et al. B-1 plasma cells require non-cognate CD4 T cell help to generate a unique repertoire of natural IgM. J Exp Med 220, doi:10.1084/jem.20220195 (2023).</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20220195</ArticleId><ArticleId IdType="pmc">PMC9960156</ArticleId><ArticleId IdType="pubmed">36811605</ArticleId></ArticleIdList></Reference><Reference><Citation>Elias S. et al. CXCR4+ Treg cells control serum IgM levels and natural IgM autoantibody production by B-1 cells in the bone marrow. J Exp Med 219, doi:10.1084/jem.20220047 (2022).</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20220047</ArticleId><ArticleId IdType="pmc">PMC9178519</ArticleId><ArticleId IdType="pubmed">35670812</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandarano A. H. et al. Myalgic encephalomyelitis/chronic fatigue syndrome patients exhibit altered T cell metabolism and cytokine associations. J Clin Invest 130, 1491&#x2013;1505, doi:10.1172/JCI132185 (2020).</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI132185</ArticleId><ArticleId IdType="pmc">PMC7269566</ArticleId><ArticleId IdType="pubmed">31830003</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>